Patents Examined by Quanglong N Truong
  • Patent number: 12005146
    Abstract: The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment (“cholestosome”) consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject.
    Type: Grant
    Filed: March 24, 2023
    Date of Patent: June 11, 2024
    Assignee: THERASYN SENSORS, INC.
    Inventors: Jerome J. Schentag, Mary P. McCourt, Lawrence Mielnicki, Julie Hughes
  • Patent number: 12005141
    Abstract: Disclosed herein is a liquid pharmaceutical formulation substantially free of water, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin. Also disclosed herein is a liquid pharmaceutical formulation substantially free of water and ethanol, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin.
    Type: Grant
    Filed: June 22, 2023
    Date of Patent: June 11, 2024
    Assignee: LIQMEDS WORLDWIDE LIMITED
    Inventors: Jayanta Kumar Mandal, Malay Patel, Swati Nagar, Michael Paul DeHart
  • Patent number: 12005035
    Abstract: Described herein is a composition that includes an N-methyl-D-aspartate receptor (NMDAR) antagonist and a TAS2R receptor response mediating agent for treating neuropathic pain and depression. Methods for treating chronic pain with the described composition are also described.
    Type: Grant
    Filed: August 14, 2023
    Date of Patent: June 11, 2024
    Inventor: Daniel C. Javitt
  • Patent number: 12004630
    Abstract: The invention relates to a system (10) for dispensing a product, comprising a dispenser that can house at least two cartridges, each of which includes a reservoir containing a base product, a first base product comprising at least 0.1 wt.-% particles having a density differential relative to the medium containing same, preferably of at least 0.5 g/cm3, in particular particles having a density greater than or equal to 2 g/cm3, and a thickening agent. The dispenser allows at least two base products to be dispensed in adjustable proportions, the viscosity of the first base product being preferably greater than 2 Pa·s and more preferably greater than or equal to 4 Pa·s.
    Type: Grant
    Filed: February 8, 2022
    Date of Patent: June 11, 2024
    Assignee: L'OREAL
    Inventors: Henri Samain, Franck Giron, Guillaume Kergosien
  • Patent number: 11998104
    Abstract: The invention relates to a system (10) for dispensing a product, comprising a dispenser that can house at least two cartridges, each of which includes a reservoir containing a base product, a first base product comprising at least 0.1 wt.-% particles having a density differential relative to the medium containing same, preferably of at least 0.5 g/cm3, in particular particles having a density greater than or equal to 2 g/cm3, and a thickening agent. The dispenser allows at least two base products to be dispensed in adjustable proportions, the viscosity of the first base product being preferably greater than 2 Pa·s and more preferably greater than or equal to 4 Pa·s.
    Type: Grant
    Filed: February 8, 2022
    Date of Patent: June 4, 2024
    Assignee: L'OREAL
    Inventors: Henri Samain, Franck Giron, Guillaume Kergosien
  • Patent number: 11998634
    Abstract: The invention relates to new emulsion formulations comprising polyethylene glycol (15)-hydroxystearate, polyglyceryl-3 oleate and one, two, three or more anti-cancer drugs as well as such emulsion formulations for use in the treatment of cancer and a method for producing such emulsion formulations. Preferably, the emulsion formulation can further comprise one or more immunomodulatory drugs or adjuvant.
    Type: Grant
    Filed: December 6, 2019
    Date of Patent: June 4, 2024
    Assignee: CAPNOPHARM GMBH
    Inventor: Ranjita Sahoo
  • Patent number: 11998555
    Abstract: Disclosed herein, in part, are liquid pharmaceutical formulations comprising furosemide or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable excipients, and a pharmaceutically acceptable buffer. Methods of treating congestion, edema, fluid overload, or hypertension in a patient in need thereof are also provided.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: June 4, 2024
    Assignee: scPharmaceuticals Inc.
    Inventors: Alfredo Grossi, Britt Kostraba, Olatokumbo O. Luca Ogunleye, Shannon Terry, Franciscus Koppenhagen
  • Patent number: 11980685
    Abstract: Certain embodiments of the present disclosure provide liquid pharmaceutical formulations, suitable for oral administration, that contain an amount of a tafamidis of from 0.5 mg/ml to 20 mg/ml, water, and an amount of an alkaline pH modifier that yields a content of the tafamidis solubilized in the water of from 0.5 mg/ml to 19.8 mg/ml.
    Type: Grant
    Filed: December 23, 2022
    Date of Patent: May 14, 2024
    Assignee: TaP Pharmaceuticals, AG
    Inventors: Nilesh Parikh, William Hite
  • Patent number: 11980277
    Abstract: The invention relates to a system (10) for dispensing a product, comprising a dispenser that can house at least two cartridges, each of which includes a reservoir containing a base product, a first base product comprising at least 0.1 wt.-% particles having a density differential relative to the medium containing same, preferably of at least 0.5 g/cm3, in particular particles having a density greater than or equal to 2 g/cm3, and a thickening agent. The dispenser allows at least two base products to be dispensed in adjustable proportions, the viscosity of the first base product being preferably greater than 2 Pa·s and more preferably greater than or equal to 4 Pa·s.
    Type: Grant
    Filed: February 8, 2022
    Date of Patent: May 14, 2024
    Assignee: L'OREAL
    Inventors: Henri Samain, Franck Giron, Guillaume Kergosien
  • Patent number: 11974651
    Abstract: The invention relates to a system (10) for dispensing a product, comprising a dispenser that can house at least two cartridges, each of which includes a reservoir containing a base product, a first base product comprising at least 0.1 wt.-% particles having a density differential relative to the medium containing same, preferably of at least 0.5 g/cm3, in particular particles having a density greater than or equal to 2 g/cm3, and a thickening agent. The dispenser allows at least two base products to be dispensed in adjustable proportions, the viscosity of the first base product being preferably greater than 2 Pa·s and more preferably greater than or equal to 4 Pa·s.
    Type: Grant
    Filed: February 8, 2022
    Date of Patent: May 7, 2024
    Assignee: L'OREAL
    Inventors: Henri Samain, Franck Giron, Guillaume Kergosien
  • Patent number: 11975021
    Abstract: Compositions for treating inflammatory skin conditions are described. The compositions can include povidone iodine in aqueous solution, hydrocortisone, diphenhydramine, an emulsifier, and a hydrophobic carrier, where the povidone iodine aqueous solution is emulsified in the hydrophobic carrier. A method of preparing a composition is also described. The method can include adding an aqueous solution of povidone iodine to a hydrophobic carrier, and adding an emulsifier to the hydrophobic carrier at a concentration that emulsifies the aqueous solution of povidone iodine in the hydrophobic carrier upon mixing.
    Type: Grant
    Filed: October 9, 2023
    Date of Patent: May 7, 2024
    Inventor: James Kojian
  • Patent number: 11975099
    Abstract: The present invention relates to an ethanol foam sclerosing agent for vascular anomalies and a preparation method thereof. The ethanol foam sclerosing agent includes absolute ethanol, water, Tween 80 and a stabilizer. The ethanol foam sclerosing agent further includes hyaluronic acid. The mass composition of the ethanol foam sclerosing agent includes 32-42% of absolute ethanol, 0.5-2% of Tween 80, 0-25% (excluding 0) of egg yolk lecithin, 0-2% (excluding 0) of hyaluronic acid, and the balance of water. The stabilizer is hyaluronic acid or glycerin. Foam is prepared by the Tessari method. While the original therapeutic effect of ethanol is not changed, the side effect of the ethanol is significantly reduced.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: May 7, 2024
    Assignee: QILU HOSPITAL OF SHANDONG UNIVERSITY
    Inventors: Shaohua Liu, Hanshu Zhang, Aijun Yang, Yiran Liu
  • Patent number: 11969426
    Abstract: The present invention relates to pharmaceutical compositions comprising Akt protein kinase inhibitors with therapeutic activity against diseases such as cancer as well as processes for their preparation and their use as medicament.
    Type: Grant
    Filed: April 19, 2022
    Date of Patent: April 30, 2024
    Assignee: Genentech, Inc.
    Inventors: Reinhard Reents, Pirmin Hidber, Andre Hell, Peter Steidle, Martin Wunderlich, Marie Pepelnjak, Francis Gosselin, Edward Yost
  • Patent number: 11957647
    Abstract: Disclosed is a pharmaceutically-acceptable composition in the form of a solid, amorphous, mono-particulate powder comprising a mixture of: (a) a pharmacologically-effective dosage amount of an adrenergic receptor modulator, or a pharmaceutically-acceptable salt thereof; and (b) a pharmaceutically-acceptable carrier material, which carrier material comprises a maltodextrin with a dextrose equivalent (DE) that is above 15. Compositions are suitable for transmucosal drug delivery, including nasal delivery, by which said compositions may be loaded into a single-use nasal applicator. Compositions are preferably made by way of spray drying and may further include a disaccharide, such as lactose or trehalose which, along with the active ingredient and maltodextrin, may be spray-dried together in combination. Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate.
    Type: Grant
    Filed: May 24, 2023
    Date of Patent: April 16, 2024
    Assignee: OREXO AB
    Inventors: Jonas Sävmarker, Robert Rönn
  • Patent number: 11957644
    Abstract: A therapeutic composition and a method of producing it by light-activating hypericin in a carrier or solvent. Preferably, the composition is made by combining dried flowers and/or flower stems of St. John's Wort with edible oil and exposing the mixture to the sun for a prolonged time. This process serves to light-activate the hypericin before its use and reduce risk of skin phototoxicity. The composition can be used for treating undesirable conditions such as mouth sores and vaginal infections.
    Type: Grant
    Filed: October 5, 2022
    Date of Patent: April 16, 2024
    Inventors: Natasa Stojanovic, Robert D. Fish
  • Patent number: 11951169
    Abstract: The present disclosure relates to a pharmaceutical composition having a mixture containing curcuminoids as at least one of the active therapeutic agents. Generally, the mixture comprises 4-8% by weight of purified curcuminoids; 20-35% by weight of an oil phase; 25-35% by weight of a co-solvent; and 40-50% by weight of a surfactant. Preferably, the purified curcuminoids in the mixture has an average size of about 19 nm or at least half of the curcuminoids carried in the mixture has particle size not exceeding 19 nm.
    Type: Grant
    Filed: January 8, 2020
    Date of Patent: April 9, 2024
    Assignee: AASTAR PTE LTD.
    Inventor: The Huy Tran
  • Patent number: 11931455
    Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.
    Type: Grant
    Filed: July 31, 2023
    Date of Patent: March 19, 2024
    Assignee: LIQMEDS WORLDWIDE LIMITED
    Inventors: Sandip Mehta, Manish Kumar Umrethia, Jayanta Mandal
  • Patent number: 11925531
    Abstract: The present disclosure provides a magnetic dressing and a preparation method and use thereof, belonging to the technical field of pharmaceutical preparations. The magnetic dressing includes a magnetic layer, a drug-loading layer, and a protective layer that are stacked in sequence, where the magnetic layer includes polyvinyl alcohol, gluten, and iron particles. In the present disclosure, a swallowed magnetic dressing is controlled by an external magnetic field, and the magnetic dressing is moved to a pathological position by changing a direction of the external magnetic field; after the external magnetic field is removed, the magnetic dressing changes from a ring to a sheet, thereby completing attachment of an entire lesion surface to complete treatment by autonomous drug release.
    Type: Grant
    Filed: September 13, 2022
    Date of Patent: March 12, 2024
    Assignee: Shanghai University
    Inventors: Na Liu, Ziheng Chen, Huiyu Yuan, Dan Zhang, Kewei Zhang, Tao Yue, Yuanyuan Liu, Yan Peng
  • Patent number: 11911347
    Abstract: The present invention is in the field of antioxidants and relates to cosmetic or pharmaceutical, preferably dermatological, compositions or homecare product comprising or consisting of a synergistic combination of a specific antioxidant and an effective amount of 1,2-heptanediol and/or 2,3-heptanediol or of a specific alkanediol or a mixture of two or more different specific alkanediols and the use of said compositions as a cosmetic, for personal care, as a pharmaceutical or homecare product, in particular for scavenging reactive oxygen species (ROS), for inhibition matrix metalloproteinases expression and/or for inhibiting interleukin 8 (IL-8) secretion.
    Type: Grant
    Filed: April 14, 2023
    Date of Patent: February 27, 2024
    Assignee: Symrise AG
    Inventors: Nikolas Bugdahn, Sven Siegel, Sabine Lange, Dominik Stuhlmann
  • Patent number: 11903935
    Abstract: The present disclosure provides compounds useful as inhibitors of SARM1 NADase activity, compositions thereof, and methods of using the same. The present disclosure provides compounds useful for treating a neurodegenerative or neurological disease or disorder, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: October 22, 2021
    Date of Patent: February 20, 2024
    Assignees: Washington University, Disarm Therapeutics, Inc.
    Inventors: Jeffrey Milbrandt, Kow Essuman, Yo Sasaki, Aaron Diantonio, Xianrong Mao, Rajesh Devraj, Raul Eduardo Krauss, Robert Owen Hughes